Approximately 10 million people are suffering from diabetes mellitus in Germany. About 15 % of them are diagnosed with diabetic foot ulcers at least once in their life which results in about 50,000 amputations per year. Further 230,000 new diabetic foot ulcer patients are recorded every year. The global prevalence of diabetes for all age-groups worldwide was estimated to be 2.8 % in 2000 and 4.4 % in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Wild et al., “The global prevalence of diabetes”, DIABETES CARE, Vol. 27, Nr. 5, 2004).
What are diabetic foot ulcers and how do they develop?Diabetic foot ulcers represent a major complication of diabetes mellitus. They result from an increased level of blood sugar that occurs in consequence of a long-term lack of insulin. In the long term, the increased blood sugar content damages nerves and blood vessels of the foot. Consequently, damaged foot nerves retard the perception of painful stimuli in the feet and minor injuries are often recognized too late. Lesions are infected, heal badly, or may not heal at all due to a disturbed blood circulation. In the worst case, the tissue dies and the affected limb needs to be amputated. As diabetic foot ulcers often concern the elderly population, aging nations urgently require a successful long-term therapy option to avoid rising amputation rates in the future.
The first therapy system to specifically utilize the biologic effects of Softwave. Demagold 100™ offers revolutionary new treatment for chronic and traumatic wounds and skin lesions.
Dermagold’s soft focused MultiWave™ technology combines heat, electromagnetic acoustic, and light energies to stimulate certain biologic effects crucial to wound healing:
Intensive research by MTS engineers produced an innovative soft focused SoftWave applicator designed specifically for skin indications, Based on proven MTS technology, . the Dermagold™ applicator delivers the specific energy volume and energy distribution specially required for treatment of skin lesions.
Treatment without Anesthesia
Because of the Dermagold™ applicator’s broad surface distribution of the treatment energy, the pain usually associated with SoftWave® treatment is significantly reduced. Thus Dermagold™ treatment for skin lesions does not require anesthesia. The number of treatments needed depends on the indication and on the wound surface.
Dermagold™ uses patented SmartTrode intelligent electrode technology. The SmartTrode adjusts itself automatically for the selected level of output power to ensure consistent and effective Softwave and thus, optimal treatment quality.